Living with
Heart Failure?

Learn about a minimally-invasive
treatment through the ALLAY-HF Study

Millions of people worldwide are living with diastolic heart failure and its troubling symptoms. People with diastolic heart failure have difficulty breathing and often struggle with simple daily activities. Medicines that are effective in treating other types of heart failure often do not work well for diastolic heart failure. However, doctors are currently researching new, non-medication options that may be able to help.

If you have diastolic heart failure, you may qualify for the ALLAY-HF Clinical Study. The study is evaluating the Alleviant System - an investigational, minimally invasive treatment designed to improve heart failure symptoms without leaving a permanent implant in the heart.

What is Diastolic Heart Failure?

Diastolic heart failure occurs when the muscles of the heart are stiffer than normal and do not relax normally. As a result, the left side of the heart may not fill as easily with blood. This increases pressure inside the left heart chambers and lungs.

People with diastolic heart failure have difficulty breathing and often struggle with simple daily activities. Medicines that are effective in treating the other types of heart failure often do not work well for diastolic heart failure and treatment options are currently very limited.

 

What is the Alleviant System?

The Alleviant System is an investigational, minimally invasive treatment designed to reduce excess pressure in the heart without leaving behind a permanent implant. The Alleviant System builds upon a previously studied treatment for heart failure called interatrial shunting. Clinical studies have shown that interatrial shunting lowers pressure within the heart and may improve heart failure symptoms and quality of life.1,2,3

The Alleviant procedure is performed by an interventional cardiologist using a non-surgical, catheter-based approach. Unlike many other shunting procedures, the Alleviant procedure does not leave behind a permanent implant in the heart.

The ALLAY-HF Clinical Study

The Alleviant System is currently being offered at select treatment centers in the US, Canada, Europe, Australia and New Zealand through the ALLAY-HF Clinical Study. If you qualify and choose to join the ALLAY-HF Study you will receive:

  • Evaluations and monitoring of your heart failure condition from a team of specialists
  • Study-related care and study-related procedures at no cost
  • Ongoing follow-up evaluations (at no cost) over a 5-year period
  • The opportunity to help advance new therapies that may improve the future management of heart failure

See If You Qualify

If heart failure is affecting your daily life, you may qualify for the ALLAY-HF Clinical Study. The study is evaluating the Alleviant System - an investigational, non-surgical treatment designed to improve heart failure symptoms without leaving a permanent implant in the heart.

To see if you might qualify for the ALLAY-HF Clinical Study, and to get connected directly with your local study center to learn more, please take the questionnaire below.

  1. Feldman, Ted, et al. “Transcatheter Interatrial Shunt Device for for the Treatment of Heart Failure with Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients with Heart Failure]).” Circulation, vol. 137, no. 4, 2018, pp. 364–375.
  2. Hasenfuß G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, Malek F, Van der Heyden J, Lang I, Petrie MC, Cleland JG, Leon M, Kaye DM; REDUCE LAP-HF study investigators. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016;387(10025):1298-304.
  3. ALLEVIATE-HF-1 and HF-2 Clinical Studies. Data on file at Alleviant Medical.